Korenev Georgiy, Gutenev Alexey A, Antipin Fyodor V, Chernyshov Vladimir V, Shulgina Julia A, Korobkina Maria P, Nawrozkij Maxim B, Ivanov Roman A
Medicinal Biotechnology Department, Sirius University of Science and Technology, Olimpiyskiy Ave. 1, 354340 Sirius, Krasnodar Region, Russia.
Molecules. 2025 Aug 14;30(16):3375. doi: 10.3390/molecules30163375.
Several approaches to the synthesis of risdiplam, a pharmacologically relevant pyridopyrimidinone derivative, have been recently reported. However, most of these routes rely exclusively on palladium-catalyzed, cross-coupling reactions and involve low-yielding intermediates, which limit their scalability and complicate impurity control. In this work, we present a five-step, straightforward route to risdiplam, utilizing ethyl 2,8-dimethylimidazo[1,2-]pyridazine-3-carboxylate-an accessible and cost-effective building block previously developed by our research group-as a starting material. The key step involves construction of the 4-pyrido[1,2-]pyrimidin-4-one scaffold via a copper(I)-catalyzed heterocyclization reaction. This represents a novel and convenient protocol for the synthesis of 2-(2,8-dimethylimidazo[1,2-]pyridazin-6-yl)-7-fluoro-4-pyrido[1,2-]pyrimidin-4-one, which serves as a crucial intermediate in the final stages of risdiplam synthesis. The overall process allows us to obtain the target compound with a 20% total yield (from abovementioned starting material) and high purity (99.86%, by HPLC-UV), with a maximum level of unidentified impurities not exceeding 0.046%. The developed approach eliminates the use of palladium catalysis and chromatographic purification, offering a practical and scalable alternative for risdiplam production.
最近报道了几种合成risdiplam(一种具有药理活性的吡啶并嘧啶酮衍生物)的方法。然而,这些路线大多仅依赖钯催化的交叉偶联反应,并且涉及低产率的中间体,这限制了它们的可扩展性并使杂质控制复杂化。在这项工作中,我们提出了一条合成risdiplam的五步直接路线,使用2,8-二甲基咪唑并[1,2 -]哒嗪-3-羧酸乙酯(我们研究小组先前开发的一种易于获得且具有成本效益的结构单元)作为起始原料。关键步骤涉及通过铜(I)催化的杂环化反应构建4-吡啶并[1,2 -]嘧啶-4-酮骨架。这代表了一种新颖且便捷的合成2-(2,8-二甲基咪唑并[1,2 -]哒嗪-6-基)-7-氟-4-吡啶并[1,2 -]嘧啶-4-酮的方法,该化合物是risdiplam合成最后阶段的关键中间体。整个过程使我们能够以20%的总收率(从上述起始原料开始)获得目标化合物,并且纯度很高(通过HPLC - UV测定为99.86%),未鉴定杂质的最大含量不超过0.046%。所开发的方法无需使用钯催化和色谱纯化,为risdiplam的生产提供了一种实用且可扩展的替代方案。